Non-Alcoholic Steatohepatitis Treatment Industry Sizeworth $15 billion by 2027

The report "Non-Alcoholic Steatohepatitis Treatment Market by Drug Class (Obeticholic Acid (OCA), Vitamin E and Pioglitazone, Distribution Channel (Hospitals, Pharmacies) – Global Forecast to 2027", global non-alcoholic steatohepatitis (NASH) treatment market is projected to reach USD 15 billion by 2027 from USD 5 billion in 2022, at a CAGR of ~25% during the forecast period

View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/non-alcoholic-steatohepatitis-treatment-market-217356730.html

Various drugs candidates are under pipeline studies are expected to be launched during the forecast period. This factor is expected to spur the market growth during the forecast period at a higher rate. Rising prevalence of the NASH is further likely to increase demand for treatment options subsequently impacting on the growth of the market. For instance, according to NASH Education Program, NASH prevalence is expected to grow by 63% between 2015 and 2030.

Vitamin E and pioglitazone segment dominated the market in 2021.

Based on drug class the market is segmented into Obeticholic Acid (OCA), Vitamin E And Pioglitazone, Lanifibranor, Semaglutide, Cenicriviroc, and Other Products. The off-label therapies are in demand owing to lack of FDA approved drugs for the NASH treatment. Vitamin E and pioglitazone are most commonly prescribed drugs for treatment of non-alcoholic steatohepatitis. Furthermore, emphasis on drugs approvals by various pharma companies is likely to upsurge the market growth in coming years. In March 2020, The Drug Controller General of India approved Zydus’ saroglitazar for non-cirrhotic non-alcoholic steatohepatitis (NASH), making it the first drug approved for this indication approved anywhere in the world.

North America dominated with the largest share of the non-alcoholic steatohepatitis (NASH) treatment market in 2021

Based on region, the non-alcoholic steatohepatitis (NASH) treatment market is segmented into North America, Europe, the Asia Pacific and ROW. North America accounted for the largest share of the non-alcoholic steatohepatitis (NASH) treatment market in 2021. The growth of the North American market is attributed to presence of major key market players coupled with increasing prevalence of NASH in the region.  Asia Pacific is expected to grow at significant rate owing to various factors such as increased investment in research & development and awareness about various treatment options available across the region.

Major players operating in the market are Astrazeneca Plc (UK), Intercept Pharmaceuticals Inc. (US), Galmed Pharmaceuticals Ltd. (Israel), Genfit Sa (France), Gilead Sciences, Inc. (US) and among others.

Don’t miss out on business opportunities in Non-Alcoholic Steatohepatitis Treatment Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com